{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:06:12Z","timestamp":1770984372632,"version":"3.50.1"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Interactions between HIV and opioid dependence therapies are known to occur. We sought to determine if such interactions occurred between methadone and elvitegravir boosted with cobicistat (EVG\/COBI). We performed a within-subject open-label pharmacokinetic and pharmacodynamic study of 11 HIV-seronegative subjects stabilized on at least 2 weeks of methadone. Subjects underwent baseline and steady-state evaluation of the effect of elvitegravir 150 mg once a day (QD) boosted with 150 mg QD of cobicistat (EVG\/COBI) on methadone pharmacokinetic parameters. Safety and pharmacodynamics were monitored throughout the study. Compared to baseline values, the\n            <jats:italic>R<\/jats:italic>\n            -methadone mean area under the concentration-time curve to the end of the dosing period (AUC\n            <jats:sub>tau<\/jats:sub>\n            ) (5,550 versus 6,210 h \u00b7 ng\/ml) and mean maximum concentration of drug in serum (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ) (316 versus 337 ng\/ml) did not significantly increase in the presence of EVG\/COBI. Compared to baseline values, the\n            <jats:italic>S<\/jats:italic>\n            -methadone mean AUC\n            <jats:sub>tau<\/jats:sub>\n            (7,040 versus 7,540 h \u00b7 ng\/ml) and mean\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            (446 versus 452 ng\/ml) did not significantly increase in the presence of EVG\/COBI. The AUC\n            <jats:sub>tau<\/jats:sub>\n            ,\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            , and\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>tau<\/jats:sub>\n            of elvitegravir and cobicistat did not significantly differ from those of historical controls. Opioid withdrawal or overdose was not observed among subjects in this study. The addition of EVG\/COBI to stabilized patients receiving methadone did not affect methadone pharmacokinetics and pharmacodynamics. These two agents can be safely coadministered.\n          <\/jats:p>","DOI":"10.1128\/aac.01229-13","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T05:19:19Z","timestamp":1380604759000},"page":"6154-6157","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone Maintenance"],"prefix":"10.1128","volume":"57","author":[{"given":"R. Douglas","family":"Bruce","sequence":"first","affiliation":[{"name":"Yale University AIDS Program, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Winkle","sequence":"additional","affiliation":[{"name":"Anaheim Clinical Trials, Anaheim, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Custodio","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Wei","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Rhee","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. P.","family":"Kearney","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ramanathan","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald H.","family":"Friedland","sequence":"additional","affiliation":[{"name":"Yale University AIDS Program, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318209751e"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2009.10.004"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17490-4"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/508181"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000219769.89679.ec"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2006.12.014"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203290-00012"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2006.0192"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090080008002"},{"key":"e_1_3_2_11_2","first-page":"282","article-title":"Pharmacologic comparison of the optical isomers of methadone","volume":"93","author":"Scott CC","year":"1948","unstructured":"ScottCC RobbinsEB ChenKK. 1948. Pharmacologic comparison of the optical isomers of methadone. J. Pharmacol. Exp. Ther. 93:282\u2013286.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.6.742"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200204000-00017"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx950116m"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181642938"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2010.00628.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3182423478"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.276"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241140-00003"},{"key":"e_1_3_2_20_2","first-page":"123","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Gonzalez F","year":"2011","unstructured":"GonzalezF CoughtrieM TukeyRH. 2011. Drug metabolism, p 123\u2013144. In GoodmanLS BruntonLL ChabnerB KnollmannBC (ed), Goodman & Gilman's the pharmacological basis of therapeutics, 12th ed. McGraw-Hill, New York, NY.","edition":"12"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn122"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/11584570-000000000-00000"},{"key":"e_1_3_2_23_2","volume-title":"Stribild, elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate","author":"Gilead Sciences","year":"2012","unstructured":"Gilead Sciences. 2012. Product Information. Stribild, elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate. Gilead Sciences, Foster City, CA."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.228"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/00952998709001515"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183628.20041.f2"},{"key":"e_1_3_2_27_2","volume-title":"13th Int. Workshop Clin. Pharmacol.","author":"Ramanathan S","year":"2012","unstructured":"RamanathanS WangH StondellT ChengA KearneyBP. 2012. Pharmacokinetics and drug interaction profile of cobicistat boosted-elvitegravir with atazanavir, rosuvastatin, or rifabutin, vol O_03. 13th Int. Workshop Clin. Pharmacol. HIV Ther. Barcelona, Spain."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/376907"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/chir.10303"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.13.18"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80058-3"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01229-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01229-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:26:18Z","timestamp":1645482378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01229-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1128\/AAC.01229-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01229-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"2013-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}